Response of stress proteins to cisplatin-based induction chemotherapy in patients with advanced cervical cancer

PERINETTI C.; CIOCCA D. R.; REAL N.; IOVANNA J; CUELLO CARRION F. D.; CASTRO G. N.

Bogotá

Congreso; Second Latin American Chapter Conference of Cell Stress Society International; 2016

Cell Stress Society International

The benefits of cisplatin-based neoadjuvant chemotherapy in women with locally advanced cervical cancer depends on timing and dose intensity of the drug. Moreover, cervical cancer is a heterogeneous disease and the biology of the cells appears to have an important impact on whether or not this treatment favors the patients. In order to understand how the cisplatin treatment affects the stress response, in this work we have initiated an exploratory study to analyze a number of stress proteins before and after chemotherapy. The study involved 10 patients, the pre-and post chemotherapy paired biopsies were examined by hematoxylin and eosin and by immunohistochemistry. The proteins evaluated were: p53, P16/INK4A, MSH2, NUPR1 (Nuclear Protein, Transcriptional Regulator, 1), and HSP27 (total and phosphorylated), these proteins were selected because there is evidence that they might be related with drug resistance. The expression levels of these proteins varied from tumor to tumor, p53 was not significantly affected by cisplatin, as well as P16/INK4A, MSH2, and NUPR1. In contrast, cytoplasmic HSP27 expression levels tended to decrease following cisplatin while HSP27 (mainly the phosphorylated form) tended to increase at nuclear level. In this communication we will also present the correlations with the histological response and the survival of the patients.